Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Reimbursement News › CMS Finalizes NGS Test National Coverage Determination, Removes Evidence Development for LDTs

CMS Finalizes NGS Test National Coverage Determination, Removes Evidence Development for LDTs

Mar 16, 2018
|
staff reporter

This article has been updated with information about NGS cancer panels with FDA-approved companion diagnostic indications.

NEW YORK (GenomeWeb) – CMS on Friday finalized the draft national coverage determination it issued last year on next-generation sequencing cancer panels, altering the determination to no longer include coverage with evidence development (CED) for tests that haven't been approved by the US Food and Drug Administration.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14
Featured Webinar

Development of a Metagenomics-based Pathogen-Detection Assay for SARS-CoV-2 Research

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In Molecular Diagnostics

  1. FDA Issues New Guidance for SARS-CoV-2 Pooled Sample Testing

  2. FDA Letter Warns About False-Positive Results From Becton Dickinson SARS-CoV-2 Test

  3. GenMark Diagnostics Preliminary Q2 Revenues Rise 118 Percent on SARS-CoV-2 Tests

  4. Thermo Fisher Scientific, Chugai Pharmaceutical Sign Companion Diagnostic Agreement for NSCLC

  5. Siemens Healthineers, EKF Diagnostics, Immucor, Horiba, Others Get FDA Clearances in June

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.